Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

Euro Surveill. 2018 Mar;23(9):18-00086. doi: 10.2807/1560-7917.ES.2018.23.9.18-00086.

Abstract

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.

Keywords: Europe; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Europe / epidemiology
  • European Union
  • Female
  • Humans
  • Infant
  • Infant, Newborn
  • Influenza A Virus, H1N1 Subtype / immunology*
  • Influenza A Virus, H1N1 Subtype / isolation & purification
  • Influenza A Virus, H3N2 Subtype / immunology*
  • Influenza A Virus, H3N2 Subtype / isolation & purification
  • Influenza B virus / immunology*
  • Influenza B virus / isolation & purification
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / adverse effects
  • Influenza Vaccines / immunology*
  • Influenza Vaccines / therapeutic use*
  • Influenza, Human / epidemiology
  • Influenza, Human / prevention & control*
  • Influenza, Human / virology
  • Male
  • Middle Aged
  • Pandemics / prevention & control
  • Seasons*
  • Treatment Outcome
  • Vaccination / statistics & numerical data

Substances

  • Influenza Vaccines